A new diagnostic technology can predict how patients will respond different drugs or drug combinations before the patients take the drugs.
Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer. This revolutionary diagnostic test will enable oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells.
The technology is based on new measurement tool, the Suspended Microchannel Resonator (SMR), invented at MIT. This tool measures the weight change of cancer cells in response to cancer drugs. It effectively incorporates all genetic biomarkers, both known and unknown, and incorporates the myriad of other factors (epigenetic, metagenetic, environmental, and any others), both known and unknown, that affect a cancer cell’s response to a cancer drug. The SMR test is so uniquely sensitive that it can weigh single cells with precision to 1 part in 10,000 (~50 femtograms), which is 10-100x better than any other single-cell-measurement tool.
Travera can pinpoint the right drugs within <2 days, even though it will take many weeks to work in the patient’s body. Because it works across many cancers and many cancer drugs, it is moving oncology from being <20% personalized to >80% personalized, guiding patients to cost-effective treatments that will help them in the now, and saving payers from paying for ineffective drugs.
A copy of a 12 page corporate investment profile is available on request. Apply to receive the report, click here.